ZYN-001
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ZYN-001, also known as Δ9-tetrahydrocannabinol D-glyceric acid ester, is a cannabinoid which was under development for the treatment of cancer pain, neuropathic pain, fibromyalgia, and Tourette's syndrome but was never marketed.[1][3][2][4][5] It was formulated as a transdermal patch.[1][2][4] The drug is a synthetic prodrug of Δ9-tetrahydrocannabinol (Δ9-THC) and acts as a cannabinoid CB1 and CB2 receptor agonist.[1][2][4][5] ZYN-001 was under development by Zynerba Pharmaceuticals.[1][3][2][4] It reached phase 1 clinical trials prior to the discontinuation of its development in 2018.[1][3][2][4] The drug was discontinued after it failed to attain target THC blood levels of 5 to 15 ng/mL in a phase 1 trial.[4]
| |
| Clinical data | |
|---|---|
| Other names | ZYN001; Δ9-Tetrahydrocannabinol D-glyceric acid ester; Δ9-THC D-glyceric acid ester; Tetrahydrocannabinol prodrug; Tetrahydrocannabinol prodrug transdermal patch; THC prodrug; THC prodrug transdermal patch |
| Routes of administration | Transdermal (patch)[1][2] |
| Drug class | Cannabinoid; Cannabinoid CB1 and CB2 receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H34O5 |
| Molar mass | 402.531 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
